From microscopic world models to real‑world products
Microscopic world models generate molecular designs; the design–experiment–learn loop supports validation and iteration.
From hits to preclinical candidates, and from enzyme design to process scale-up, AI-designed products are moving toward real-world use.
Drug discovery Biomedicine: from design to the clinic
Programs are grouped by therapeutic area, with modality, stage and indication for each.
Modality
Exploratory
Hits
Leads
PCC
IND Enabling
Indication
Autoimmunity & Neurology
Undisclosed
Undisclosed
BsAb
IBD
BsAb
COPD
BsAb
COPD
BsAb
Migraine
IgG
Autoimmune
Cancer
IgG
Cancer
TCE
Prostate cancer
TCE
Prostate cancer
TCE
Gastrointestinal cancers
Metabolism
VHH
Obesity
VHH
Obesity
Completed
In progress
Planning
Each row represents a separate program, including rows with the same modality and indication. Bars show development positions, not completion percentages or clinical approval.
Synthetic biology Synthetic biology: from design to manufacturing
Programs are grouped by application, with progress across enzyme mining, laboratory scale, pilot scale and industrial scale-up.
Program
Enzyme mining
Laboratory scale
Pilot scale
Industrial scale-up
Food and health supplement ingredients
α-ketoglutaric acid
Dietary supplement ingredient
Multifunctional antioxidant
APIs and pharmaceutical intermediates
(+)-Borneol (natural borneol)
Caffeic acid
Natural ingredients for traditional Chinese medicine
Antibiotic intermediate
Agricultural biologicals
Chitinase
Crop growth promoter
Completed
In progress
Planning
Bars show each program’s position along the process stages. They do not indicate completion percentages, production volumes or commercial outcomes.